步长制药：参股公司上市致交易性金融资产预计损失2.93亿元

Core Viewpoint - The announcement indicates that the company, Buchang Pharma, has a stake in Qilukang Digital Healthcare, which is set to go public on NASDAQ on October 8, 2025, through its controlling company, Shiliu Cloud Medical [1] Financial Impact - As of September 30, 2025, the book value of the company's investment in Qilukang Digital Healthcare is 326 million yuan [1] - By December 31, 2025, the market value of the corresponding equity held by the company is expected to be 33.08 million yuan [1] - The company anticipates recognizing a fair value change loss of 293 million yuan, which will reduce the net profit attributable to the parent company for the year 2025 by the same amount, although it will not affect the net profit after deducting non-recurring gains and losses [1]